SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 23, 2007
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-31979 | 84-1460811 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
3200 Walnut Street, Boulder, Colorado | 80301 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (303) 381-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On April 23, 2007, Array BioPharma Inc. issued a press release announcing that it has filed a preliminary prospectus supplement with the Securities and Exchange Commission for the sale of 7,000,000 shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. The full text of this press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARRAY BIOPHARMA INC. |
||||
Date: April 23, 2007 |
By: |
/s/ Robert E. Conway Robert E. Conway Chief Executive Officer |
3
Exhibit No. |
|
|
---|---|---|
99.1 | Press release dated April 23, 2007 entitled "Array BioPharma Inc. Announces Proposed Public Offering of Common Stock." |
4